Medprin Regenerative Medical Technologies Co. Ltd. - Asset Resilience Ratio
Medprin Regenerative Medical Technologies Co. Ltd. (301033) has an Asset Resilience Ratio of 19.31% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Medprin Regenerative Medical Technologie total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Medprin Regenerative Medical Technologies Co. Ltd.'s Asset Resilience Ratio has changed over time. See shareholders equity of Medprin Regenerative Medical Technologie for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Medprin Regenerative Medical Technologies Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Medprin Regenerative Medical Technologie market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥155.45 Million | 19.31% |
| Total Liquid Assets | CN¥155.45 Million | 19.31% |
Asset Resilience Insights
- Good Liquidity Position: Medprin Regenerative Medical Technologies Co. Ltd. maintains a healthy 19.31% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Medprin Regenerative Medical Technologies Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Medprin Regenerative Medical Technologies Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for Medprin Regenerative Medical Technologies Co. Ltd. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Medprin Regenerative Medical Technologies Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.25% | CN¥137.85 Million ≈ $20.17 Million |
CN¥799.23 Million ≈ $116.95 Million |
-7.25pp |
| 2023-12-31 | 24.50% | CN¥192.82 Million ≈ $28.22 Million |
CN¥786.97 Million ≈ $115.16 Million |
+4.76pp |
| 2022-12-31 | 19.74% | CN¥147.07 Million ≈ $21.52 Million |
CN¥744.92 Million ≈ $109.01 Million |
-30.55pp |
| 2021-12-31 | 50.29% | CN¥375.57 Million ≈ $54.96 Million |
CN¥746.78 Million ≈ $109.28 Million |
+6.51pp |
| 2020-12-31 | 43.78% | CN¥199.33 Million ≈ $29.17 Million |
CN¥455.34 Million ≈ $66.63 Million |
-1.15pp |
| 2019-12-31 | 44.93% | CN¥152.77 Million ≈ $22.36 Million |
CN¥340.05 Million ≈ $49.76 Million |
-- |
About Medprin Regenerative Medical Technologies Co. Ltd.
Medprin Regenerative Medical Technologies Co., Ltd. engages in the research, development, manufacture, and sale of implantable medical devices. The company offers artificial dura matermembrane patches, craniomaxillofacial repair and fixation systems, and absorbable regenerative oxidation for neurosurgery meningeal repair, skull repair fixation and rapid hemostasis, etc. It also offers ReDura, a S… Read more